Welcome to MyElanco Ireland!

The MyElanco Ireland website is intended for veterinary professionals and prescribers of animal health products. By continuing to MyElanco you are confirming your professional status as one of the above. 

Getting itchy dogs back to normal

Zenrelia™ gets nearly 50% more itchy dogs back to normal than Apoquel®1††

Zenrelia gets more dogs back to normal than Apoquel

A higher proportion of dogs treated with Zenrelia achieved a PVAS (Pruritis Visual Analogue Scale) score of less than two by day 112, compared to dogs treated with Apoquel. A 'normal' itch score is considered to be comparable to that of a healthy, non-allergic dog (PVAS<2)1.

Zenrelia brand colour border

Zenrelia is highly rated by both dog owners and vets1

When dog owners were asked 'How much has your dog improved?', Zenrelia scored significantly higher than Apoquel

Graph to show how pet owners rate improvement in their dog's itch - Apoquel vs Zenrelia

Zenrelia offers significant improvement in skin lesions vs. Apoquel from day 281†††

The Canine Atopic Dermatitis Extent & Severity Index (CADESI) is a tool to help measure the level of skin lesions in dogs, used widely in clinical studies.4

Vet-assessed skin lesion score (CADESI-04)

Graph to show vet-assessed skin lesion scores (CADESI-04)

Study Design and Key Inclusion/Exclusion Criteria1

Questions?

* Referenceable claims in digital & social copy can be found on this page. Full reference list below.

** 77% of dogs treated with Zenrelia achieved PVAS <2 by day 112 compared to 53% of dogs treated with Apoquel. A ‘normal’ itch score is considered to be comparable to that of a healthy, non-allergic dog (PVAS <2)1.

BID, twice-daily; IRTT, investigator-assessed response to treatment; ORTT, owner-assessed response to treatment; SID, once daily; VAS, visual analogue scale.

Response to treatment was assessed using a simple VAS scale graded from 'no improvement' at 0 cm to 'excellent improvement' at 10 cm1

††A ‘normal’ itch score is considered to be comparable to that of a healthy, non-allergic dog (PVAS<2)1.

†††Improvement based on mean CADESI-04 scores from Day 28. A CADESI-04 score of <10 is comparable to that of a healthy, non-allergic dog1.

79% of owners expect a PVAS of 0-1.92.

¥ Multiple JAK enzymes are involved in itch and inflammation, in particular JAK1,JAK2 & TYK211.

α Proinflammatory & pruritogenic cytokines implicated in allergic skin disease & allergic responses include IL-2, IL-6, IL-4,, IL-13 & IL-316.


  1. Forster S et al. Vet Dermatol 2025 Apr,36(2):165-176.
  2. Rybnícek J. et al. Vet Dermatol 2009;20(2):115–122.
  3. Hill P. B. et al. Vet Dermatol 2007;18(5):301–308.
  4. Olivry T et al. Vet Dermatol. 2014 Apr;25(2):77–85, e25.Schwartz DM et al. 
  5. Unpublished data: JAK selectivity profile report.
  6. Gonzalez AJ et al. J. vet. Pharmacol. Therap. 37, 317--324. 
  7. Howell MD, Kuo FI and Smith PA. Front. Immunol 2019;10:2342. doi: 10.3389/fimmu.2019.02342.
  8. Zenrelia Summary of Product Characteristics.
  9. Virtanen A, et al. Arthritis & Rheumatology. 2023 Nov;75(11):2054-61.
  10. Bonelli M, et al. Ann Rheum Dis 2024;83:139-160.
  11. Lin CM, Cooles FA, Isaacs JD. Mediterr J Rheumatol. 2020 Jun 11;31(Suppl 1):100-104.

Connect with Elanco

PM-IE-25-0124

2025 may

© 2025 Elanco or its affiliates.